First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
ORACEA is a trademark of Galderma Holdings, S.A.
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
